Sandoz CEO has publicly downplayed the risk of proposed US tariffs on imported generic medicines, stating that the measures do not pose a threat to the Swiss pharmaceutical group’s operations.
The comments come as Washington signals it may impose duties of up to 200% on off-patent drugs, a policy shift that has raised concerns across the global generics supply chain.
The executive argued that the industry’s current pricing structure is adequate, noting that research-based pharmaceutical companies are already generating sufficient profits.
The executive argued that the industry’s current pricing structure is adequate, noting that research-based pharmaceutical companies are already generating sufficient profits.
Rather than accepting higher costs for consumers, the Sandoz chief called for increased investment in antibiotic development, highlighting a divergence in priorities between US trade policy and European pharmaceutical leadership.
The remarks follow escalating rhetoric from the US administration regarding trade imbalances in the healthcare sector.
While the threat of steep tariffs has weighed on sentiment for generic drug manufacturers, Sandoz’s leadership appears confident that the company’s market position and pricing power will insulate it from immediate financial harm.